Breye Therapeutics has announced that danegaptide, a potential oral treatment for nonproliferative diabetic retinopathy, has ...

Intravitreally Injected Plasmonic Nanorods Activate Bipolar Cells with Patterned Near-Infrared Laser Projection. Journal: ACS Nano Published: 2025-03-20 DOI: ...

SHANGHAI and BOSTON, Oct. 19, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases ...

SHANGHAI and BOSTON, July 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique a ...

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA, speaks about 4D-150, a novel intravitreally administered gene therapy for wet age ...

4DMT’s intravitreally-delivered choroideremia clinical candidate, 4D-110, is the first collaboration program; IND-enabling studies and activities are underway. Additional ...

NEW ORLEANS — Parallel studies testing separate regimens of aflibercept injections against laser photocoagulation found both drug regimens to work better than laser photocoagulation in ...

While there has been successful development of intravitreally administered products, injected directly into the eye, for patients with late-stage disease, ...

Skyline Therapeutics Receives FDA Clearance of IND for SKG0106, a Novel Intravitreally Delivered AAV Gene Therapy Candidate for Neovascular Age-related Macular Degeneration.

Investigating potential for an oral treatment in diabetic retinopathy ; First patient dosed in Phase 1b/2a clinical trial; Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...